Under this licence, Mesoblast will now make MPC products commercially available to doctors and hospitals across Australia for a patient’s own, or autologous, use in the repair and
Gilead Sciences has posted a net income of $712.1m for the second quarter 2010, or $0.79 per diluted share, compared to $571.4m, or $0.61 per diluted share, for
Amylin Pharma has posted a net loss, excluding a restructuring charge of $3.4m. Non-GAAP operating loss was $7.4m, a 67% improvement compared to $22.4m for the same period
Mylan said that following the settlement agreement, it is expected to get the right to market Memantine HCl in the US on January 11, 2015, or earlier, under
The study is part of a global collaboration and licensing agreement signed between Merrimack and Sanofi-aventis for MM-121 in 2009. Merrimack said that MM-121 is an antibody that
Sigma-Aldrich’s reported and organic sales for specialty fine chemicals (SAFC) increased by 10% and 11% respectively. Research product sales increased by 5% on both a reported and organic
The agreement funds research at the Gladstone Center for Translational Research led by Gladstone investigator Katerina Akassoglou, PhD and establishes the new Lundbeck Center for Neurovascular and Immuno-imaging
John O’Keefe, CEO of ITelagen, said: “Medficiency has strong established relationships with providers throughout the Mid-Atlantic and Northeast corridor and is a trusted source for their physician clients.
The drug is the generic equivalent of Sandoz’s reference listed drug (RLD) Phentermine Hydrochloride capsules USP, 30mg. Phentermine Hydrochloride, an appetite suppressant of the amphetamine and phenethylamine class,
ASG-5ME Phase I study, expected to recruit about 50 patients at multiple centers in the US, is a single-agent, open-label, dose-escalation study that will assess the safety and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.